Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer

Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma.

Source: CancerNetwork - July 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news